Betül Merd
Research Subjects
Betül Merd has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Cevat Yazici
Department of Biochemistry, Faculty of Medicine, Erciyes University, Kayseri, Turkey
1 shared publication - Fatmanur Merd
Independent Psychologist Kayseri Türkiye
1 shared publication - Füsun Ferda Erdoğan
Department of Neurology Erciyes University School of Medicine Kayseri Turkey
1 shared publication - Inayet Gunturk
Department of Midwifery, Faculty of Health Sciences, Nigde Omer Halisdemir University, Nigde Zubeyde Hanım, Nigde
1 shared publication - Meltem Sönmez
Faculty of Medicine, Department of Biostatistics, Erciyes University, Kayseri, Turkey
1 shared publication - Şeyma Benli
Department of Neurology Afşin State Hospital Kahramanmaraş Turkey
1 shared publication
Latest Publications
- Open Access
- 8 July 2026
- Published by Wiley in Epileptic Disorders
Peripheral inflammatory markers and metabolic profiles in temporal lobe epilepsy and functional dissociative seizures
Background: Temporal lobe epilepsy (TLE) and functional dissociative seizures (FDS) are distinct conditions that share overlapping clinical, neuropsychiatric, and biological features, including depressive symptoms, obesity‐related metabolic dysregulation, and alterations in systemic inflammatory markers. Understanding the interplay among these factors may provide insight into their shared biological burden. Objective: This study aimed to investigate the relationships among systemic inflammatory markers, adipokines, obesity, seizure frequency, and depressive symptom burden in patients with drug‐resistant TLE, drug‐responsive TLE, and FDS. Methods: Seventy‐four patients were enrolled and divided into three groups: drug‐resistant TLE ( n = 24), drug‐responsive TLE ( n = 25), and FDS ( n = 25). Demographic and clinical data, physical activity levels, and depression scores were collected. Serum levels of IL‐1β, IL‐6, TNF‐α, BDNF, leptin, and adiponectin were measured using ELISA. Group comparisons were initially performed using One‐Way ANOVA or Kruskal‐Wallis tests. Multiple linear regression models were subsequently constructed to adjust for potential confounders, including age, sex, and body mass index (BMI). Adjusted p values < 0.05 were considered statistically significant. Results: In crude analyses, IL‐1β, leptin, and adiponectin levels differed significantly across groups. However, after adjustment for age, sex, and BMI, only leptin (adjusted p = 0.014) and adiponectin (adjusted p = 0.005) remained significantly associated with the diagnostic group. The difference in IL‐1β levels did not retain statistical significance after adjustment (adjusted p = 0.067). IL‐6, TNF‐α, and BDNF levels did not differ significantly between groups in either crude or adjusted analyses. Beck Depression Inventory scores were numerically higher in the FDS and drug‐resistant TLE groups, but the difference did not reach statistical significance. No significant differences were observed in BMI or physical activity levels, and the majority of participants were classified as overweight or having stage 1 obesity. Conclusion: After controlling for age, sex, and BMI, metabolic markers—particularly leptin and adiponectin—remained independently associated with diagnostic group, whereas inflammatory cytokines did not demonstrate robust independent differences. These findings suggest that metabolic dysregulation may represent a more prominent differentiating factor than systemic inflammation among patients with TLE and FDS.
- 8 July 2026
- Published by Wiley in Epileptic Disorders
Open AccessPeripheral inflammatory markers and metabolic profiles in temporal lobe epilepsy and functional dissociative seizures
Background: Temporal lobe epilepsy (TLE) and functional dissociative seizures (FDS) are distinct conditions that share overlapping clinical, neuropsychiatric, and biological features, including depressive symptoms, obesity‐related metabolic dysregulation, and alterations in systemic inflammatory markers. Understanding the interplay among these factors may provide insight into their shared biological burden. Objective: This study aimed to investigate the relationships among systemic inflammatory markers, adipokines, obesity, seizure frequency, and depressive symptom burden in patients with drug‐resistant TLE, drug‐responsive TLE, and FDS. Methods: Seventy‐four patients were enrolled and divided into three groups: drug‐resistant TLE ( n = 24), drug‐responsive TLE ( n = 25), and FDS ( n = 25). Demographic and clinical data, physical activity levels, and depression scores were collected. Serum levels of IL‐1β, IL‐6, TNF‐α, BDNF, leptin, and adiponectin were measured using ELISA. Group comparisons were initially performed using One‐Way ANOVA or Kruskal‐Wallis tests. Multiple linear regression models were subsequently constructed to adjust for potential confounders, including age, sex, and body mass index (BMI). Adjusted p values < 0.05 were considered statistically significant. Results: In crude analyses, IL‐1β, leptin, and adiponectin levels differed significantly across groups. However, after adjustment for age, sex, and BMI, only leptin (adjusted p = 0.014) and adiponectin (adjusted p = 0.005) remained significantly associated with the diagnostic group. The difference in IL‐1β levels did not retain statistical significance after adjustment (adjusted p = 0.067). IL‐6, TNF‐α, and BDNF levels did not differ significantly between groups in either crude or adjusted analyses. Beck Depression Inventory scores were numerically higher in the FDS and drug‐resistant TLE groups, but the difference did not reach statistical significance. No significant differences were observed in BMI or physical activity levels, and the majority of participants were classified as overweight or having stage 1 obesity. Conclusion: After controlling for age, sex, and BMI, metabolic markers—particularly leptin and adiponectin—remained independently associated with diagnostic group, whereas inflammatory cytokines did not demonstrate robust independent differences. These findings suggest that metabolic dysregulation may represent a more prominent differentiating factor than systemic inflammation among patients with TLE and FDS.